MORE DRUG PROPAGANDA AND LIES!

As those who claim the government entities charged with the ensuring the safety of medicine, … that they are not doing enough to study the safety of their particular drug-of-choice, (most all – marijuana).

Periodically, I attempt to point out here, their claims are lies …

I was a user back when those leading the movement to legalize pot said they were going to claim pot was medicinal and that they felt that was “the weak link” in the government’s protecting the public. Now that those promoting legalization have been successful, it’s time to re-evaluate!

Two of these “studies”, I suspect, (listed below – # 18 & 19), are prime examples of legalizers getting federal grant money to promote their pre-conceived views. If you peruse the entire list, I suspect you’ll find others, but the question is: should our tax money continue being spent this way after over 33,000 studies have shown the harm done and almost zero benefit?

Below, are 173 different studies (funded by grants / tax money). This month, I’m only listing the names of the studies – if they want to peruse the science, they can do the work! I’m tired of their LIES!

Like children demanding instant gratification, reminiscent of tobacco manufacturers a few decades back, their well-funded backers hire “scientists” to produce bogus studies, intent on legalizing another harmful drug, one known to be responsible for numerous mental issues is bringing even more immediate harm as the potency increases exponentially!

 

  1. Recreational drugs: a new health hazard for patients with concomitant chronic liver diseases.
  2. Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms.
  3. Be wary of “prescribing” medical marijuana, CMA warns.
  4. Investigation of the in vitro toxicological properties of the synthetic cannabimimetic drug CP-47,497-C8.
  5. Cannabis abuse and age at onset in schizophrenia patients with large, rare copy number variants.
  6. Changing motives for use: Outcomes from a cognitive-behavioral intervention for marijuana-dependent adults.
  7. Elevated homocysteine level in first-episode schizophrenia patients-the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse.
  8. Neuroimaging in Alcohol and Drug Dependence.
  9. THE EFFECT OF NONCOGNITIVE TRAITS ON HEALTH BEHAVIOURS IN ADOLESCENCE.
  10. Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids.
  11. Systematic review of N-acetylcysteine in the treatment of addictions.
  12. Comorbid psychiatric disorders and stages of change in cannabis-dependent, treatment-seeking patients.
  13. Can Physical Exercise or Food Deprivation Cause Release of Fat-Stored Cannabinoids in Humans?
  14. Demographic and clinical characteristics of young people seeking help at youth mental health services: baseline findings of the Transitions Study.
  15. Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex<sup>®</sup>): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis.
  16. Detainees in police custody in the Paris, France area: medical data and high-risk situations (a prospective study over 1 year).
  17. The effect of medical marijuana laws on crime: evidence from state panel data, 1990-2006.
  18. High time for advancing marijuana research.
  19. Federal red tape ties up marijuana research.
  20. Canadian court decision challenges new rules on medical marijuana.
  21. Cannabinoid Hyperemesis Syndrome: A Case Report and Review of Pathophysiology.
  22. Acute cocaine-related health problems in patients presenting to an urban emergency department in Switzerland: a case series.
  23. Medicinal marijuana found ineffective for relief of rheumatoid conditions.
  24. On the Pervasiveness of Event-Specific Alcohol Use, General Substance Use, and Mental Health Problems as Risk Factors for Intimate Partner Violence.
  25. Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
  26. Ecological factors and adolescent marijuana use: results of a prospective study in santiago, chile.
  27. Right Upper-Quadrant Pain in a Patient with Drug Abuse, Secondary Syphilis and Occult Hepatitis B Virus.
  28. Alcohol Use Trajectories After High School Graduation Among Emerging Adults With Type 1 Diabetes.
  29. Negative Cognitions as a Moderator in the Relationship Between PTSD and Substance Use in a Psychiatrically Hospitalized Adolescent Sample.
  30. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011.
  31. Contact urticaria to Cannabis sativa due to a lipid transfer protein (LTP).
  32. Temporal associations between substance use and delinquency among youth with a first time offense.
  33. Transitions in Gambling Participation During Late Adolescence and Young Adulthood.
  34. Factors Associated With Substance Use in Adolescents With Eating Disorders.
  35. Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers.
  36. Early adolescent substance use as a risk factor for developing conduct disorder and depression symptoms.
  37. Prescription drug misuse and sexual risk behaviors among adolescents and emerging adults.
  38. ADHD symptoms, autistic traits, and substance use and misuse in adult Australian twins.
  39. Medical Marijuana and Driving: a Review.
  40. HIV-1 DNA levels in peripheral blood mononuclear cells and cannabis use are associated with intermittent HIV shedding in semen of men who have sex with men on successful antiretroviral regimens.
  41. Emotional processing deficits in chronic cannabis use: A replication and extension.
  42. The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study.
  43. Examining Associations Between Cognitive-Affective Vulnerability and HIV Symptom Severity, Perceived Barriers to Treatment Adherence, and Viral Load Among HIV-Positive Adults.
  44. Cellular approaches to the interaction between cannabinoid receptor ligands and nicotinic acetylcholine receptors.
  45. Spontaneous pneumomediastinum.
  46. Diffuse Alveolar Hemorrhage (DAH) and Goodpasture Disease: Seek and You Will Find!
  47. The culpability of drivers killed in New Zealand road crashes and their use of alcohol and other drugs.
  48. Caution urged in interpreting a negative study of cannabis use and schizophrenia.
  49. Social Norms in the Development of Adolescent Substance Use: A Longitudinal Analysis of the International Youth Development Study.
  50. Long-Term Effects of Cannabis on Brain Structure.
  51. Fetal cannabinoid receptors and the “dis-joint-ed” brain.
  52. Prevalence of Illicit Drug Use in Pregnant Women in a Wisconsin Private Practice Setting.
  53. Re: Caution urged in interpreting a negative study of cannabis use and schizophrenia: A response to Dr. Christine Miller.
  54. Alternative Tobacco Use among College Students: Who is at Highest Risk?
  55. Maternal and personal religious engagement as predictors of early onset and frequent substance use.
  56. Physical activity and cannabis cessation.
  57. How long should infants at risk of drug withdrawal be monitored after birth?
  58. Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: A randomized study.
  59. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study.
  60. Cognitive performance profiles by latent classes of drug use.
  61. Alcohol and substance use among transgender women in San Francisco: Prevalence and association with human immunodeficiency virus infection.
  62. Adversity, cannabis use and psychotic experiences: evidence of cumulative and synergistic effects.
  63. Δ9-THC exposure attenuates aversive effects and reveals appetitive effects of K2/’Spice’ constituent JWH-018 in mice.
  64. Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System.
  65. Neurocognition in college-aged daily marijuana users.
  66. Intellectual, neurocognitive, and academic achievement in abstinent adolescents with cannabis use disorder.
  67. Effectiveness of training family physicians to deliver a brief intervention to address excessive substance use among young patients: a cluster randomized controlled trial.
  68. Primary Care Behavioral Interventions to Prevent or Reduce Illicit Drug Use and Nonmedical Pharmaceutical Use in Children and Adolescents: A Systematic Evidence Review for the U.S. Preventive Services Task Force.
  69. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study.
  70. Explaining Racial/Ethnic Differences in Adolescent Substance Abuse Treatment Completion in the United States: A Decomposition Analysis.
  71. A Quantitative Exploration of Attitudes Out of Line with the Prevailing Norms Toward Alcohol, Tobacco, and Cannabis Use Among European Students.
  72. Health impact of sport and exercise in emerging adult men: a prospective study.
  73. Cannabis use among a sample of 16 to 18 year-old students in Switzerland.
  74. Cannabis use and violence: Is there a link?
  75. Validation of French and German versions of a Perceived Neighborhood Social Cohesion Questionnaire among young Swiss males, and its relationship with substance use.
  76. Is the Clinical Use of Cannabis by Oncology Patients Advisable?
  77. Therapeutic Potential of Cannabinoids in Schizophrenia.
  78. Cannabis and the adolescent brain.
  79. Latent Classes of Young Adults Based on Use of Multiple Types of Tobacco and Nicotine Products.
  80. Association of race and age with treatment attendance and completion among adult marijuana users in community-based substance abuse treatment.
  81. Cannabinoids for epilepsy.
  82. The dilemma of medical marijuana use by rheumatology patients.
  83. Mechanisms and Pharmacology of Neuropathic Pain in Multiple Sclerosis.
  84. Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use.
  85. CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex.
  86. Relationship between working-memory network function and substance use: a 3-year longitudinal fMRI study in heavy cannabis users and controls.
  87. Allergy to illicit drugs and narcotics.
  88. Comparing Factor, Class, and Mixture Models of Cannabis Initiation and DSM Cannabis Use Disorder Criteria, Including Craving, in the Brisbane Longitudinal Twin Study.
  89. Outcomes for older trauma patients in the emergency department screening positive for alcohol, cocaine, or marijuana use.
  90. Rates of substance use of american Indian students in 8th, 10th, and 12th grades living on or near reservations: update, 2009-2012.
  91. A Cause for Concern: Male Couples’ Sexual Agreements and Their Use of Substances with Sex.
  92. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana: what cardiologists need to know.
  93. Marijuana Smoking is Associated With Atrial Fibrillation.
  94. A PCR marker Linked to a THCA synthase Polymorphism is a Reliable Tool to Discriminate Potentially THC-Rich Plants of Cannabis sativa L.
  95. Clearing the smoke: What do we know about adolescent cannabis use and schizophrenia?
  96. The privileged normalization of marijuana use – an analysis of Canadian newspaper reporting, 1997-2007.
  97. White matter abnormalities and cognitive impairment in early-onset schizophrenia-spectrum disorders.
  98. Different dopaminergic abnormalities underlie cannabis dependence and cannabis-induced psychosis.
  99. The mismatch negativity: a translational probe of auditory processing in cannabis users.
  100. The endocannabinoid anandamide inhibits voltage-gated sodium channels nav1.2, nav1.6, nav1.7, and nav1.8 in Xenopus oocytes.
  101. Urological complications of illicit drug use.
  102. Cannabis use associated with capsular warning syndrome and ischemic stroke.
  103. Simultaneous determination of Δ9-tetrahydrocannabinol, cannabidiol, cannabinol and 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid in hair using liquid chromatography-tandem mass spectrometry.
  104. Characterization of 15 STR cannabis loci: nomenclature proposal and SNPSTR haplotypes.
  105. Effects of Hemp (Cannabis sativa L.) Seed Oil Press-Cake and Decaffeinated Green Tea Leaves (Camellia sinensis) on Functional Characteristics of Gluten-Free Crackers.
  106. Cannabis legalization and public health: legal niceties, commercialization and countercultures.
  107. Some critical issues in cannabis policy reform.
  108. Treaties (probably) not an impediment to ‘legal’ cannabis in Washington and Colorado.
  109. New regulated markets for recreational cannabis: public health or private profit?
  110. The difficulty of restricting promotion of legalized marijuana in the United States.
  111. The powerful mix of capital and cannabis culture.
  112. Trend analysis of anonymised pooled urine from portable street urinals in central London identifies variation in the use of novel psychoactive substances.
  113. The effects of medical marijuana laws on potency.
  114. Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms.
  115. Trends in alcohol and other drugs detected in fatally injured drivers in the United States, 1999-2010.
  116. Motor Cortical Excitability Assessed by Transcranial Magnetic Stimulation in Psychiatric Disorders: A Systematic Review.
  117. Epidemiological, neurobiological, and genetic clues to the mechanisms linking cannabis use to risk for nonaffective psychosis.
  118. Cannabis use, gender and age of onset of schizophrenia: Data from the ÆSOP study.
  119. Effect of nicotine replacement therapy on quitting by young adults in a trial comparing cessation services.
  120. Pathological findings in 2 cases of fatal 25I-NBOMe toxicity.
  121. Losing faith and finding religion: religiosity over the life course and substance use and abuse.
  122. The co-use of tobacco and cannabis among adolescents over a 30-year period.
  123. Multiple and substitute addictions involving prescription drugs misuse among 12th graders: gateway theory revisited with market basket analysis.
  124. Investigation of sex-dependent effects of cannabis in daily cannabis smokers.
  125. Prevalence and correlates of alcohol and cannabis use disorders in the United States: results from the national longitudinal study of adolescent health.
  126. Recent cannabis use among adolescent and young adult immigrants in the Netherlands–the roles of acculturation strategy and linguistic acculturation.
  127. Cannabis controversies: how genetics can inform the study of comorbidity.
  128. Early adolescent patterns of alcohol, cigarettes, and marijuana polysubstance use and young adult substance use outcomes in a nationally representative sample.
  129. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
  130. Risks, prices, and positions: A social network analysis of illegal drug trafficking in the world-economy.
  131. Acute administration of Δ⁹ tetrahydrocannabinol does not prevent enhancement of sensory gating by clozapine in DBA/2 mice.
  132. Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD.
  133. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease.
  134. Do motivation deficits in schizophrenia-spectrum disorders promote cannabis use? An investigation of behavioural response to natural rewards and drug cues.
  135. Marijuana and lung diseases.
  136. Comorbidity of severe psychotic disorders with measures of substance use.
  137. Patterns of drug and alcohol use associated with lifetime sexual revictimization and current posttraumatic stress disorder among three national samples of adolescent, college, and household-residing women.
  138. Binge drinking and marijuana use among menthol and non-menthol adolescent smokers: findings from the Youth Smoking Survey.
  139. Cannabis use motives and personality risk factors.
  140. Health correlates of co-occurring substance use for women with HIV in cocaine use recovery.
  141. IBD: Patients with IBD find symptom relief in the Cannabis field.
  142. Cannabis use expectancies mediate the relation between depressive symptoms and cannabis use among cannabis-dependent veterans.
  143. Daily Use, Especially of High-Potency Cannabis, Drives the Earlier Onset of Psychosis in Cannabis Users.
  144. Cannabis-related working memory deficits and associated subcortical morphological differences in healthy individuals and schizophrenia subjects.
  145. Cannabis use disorders are comparatively prevalent among nonwhite racial/ethnic groups and adolescents: a national study.
  146. Central retinal vein occlusion in a young patient following cannabis smoke inhalation.
  147. Reference ranges for urinary levels of testosterone and epitestosterone, which may reveal gonadal function, in a Korean male population.
  148. Self-reported recent testing and diagnosis for sexually transmitted infections among regular ecstasy users in Australia, 2011-2012.
  149. A systematic review of computerised serious educational games about alcohol and other drugs for adolescents.
  150. Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: Involvement of 5HT1A receptors and previous stressful experience.
  151. Situational determinants of use and treatment outcomes in marijuana dependent adults.
  152. Adolescent predictors and environmental correlates of young adult alcohol use problems.
  153. Marijuana and self-regulation: examining likelihood and intensity of use and problems.
  154. Expectancies for smoking cessation among drug-involved smokers: implications for clinical practice.
  155. Sport participation and alcohol and illicit drug use in adolescents and young adults: a systematic review of longitudinal studies.
  156. Integrated cognitive behavioral therapy for cannabis use and anxiety disorders: rationale and development.
  157. Cannabis withdrawal syndrome: An important diagnostic consideration in adolescents presenting with disordered eating.
  158. Prevalence of alcohol and other drugs and the concentrations in blood of drivers killed in road traffic crashes in Sweden.
  159. Prevalence of and risk factors for substance use among perinatally human immunodeficiency virus-infected and perinatally exposed but uninfected youth.
  160. “Every ‘Never’ I Ever Said Came True”: Transitions from opioid pills to heroin injecting.
  161. Sex-dependent long-term effects of adolescent exposure to THC and/or MDMA on neuroinflammation and serotoninergic and cannabinoid systems in rats.
  162. Investigation of cannabis biomarkers and transformation products in waters by liquid chromatography coupled to time of flight and triple quadrupole mass spectrometry.
  163. Alterations of prefrontal cortex GABAergic transmission in the complex psychotic-like phenotype induced by adolescent delta-9-tetrahydrocannabinol exposure in rats.
  164. Legalizing a market for cannabis for pleasure: Colorado, Washington, Uruguay and beyond.
  165. Spice/K2 drugs–more than innocent substitutes for marijuana.
  166. Feasibility of teaching motivational interviewing to parents of young adults with recent-onset schizophrenia and co-occurring cannabis use.
  167. Trajectories of substance use among young American Indian adolescents: patterns and predictors.
  168. Subtypes of attention deficit-hyperactivity disorder (ADHD) and cannabis use.
  169. Use transition between illegal drugs among Brazilian university students.
  170. The hypocretin/orexin receptor-1 as a novel target to modulate cannabinoid reward.
  171. Chronic effects of cannabis use on the auditory mismatch negativity.
  172. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms.
  173. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies.
Advertisements

About josiahe

Watching closely, working to understand all I may, in this "Age of Information", even from my limited view, I can see much of what's going on ..... and I oft see it's going to impact all of us which is why I share it. My focus is to expose evil, and to serve my Lord and savior Jesus in whatever way He shows me. If one waits long enough, better writers will come along and comment; it's just that I have so little patience with the evil that lurks among us and I've wasted so much time and now, there is so little left! WELCOME!
This entry was posted in a href="http://www.startranking.com">search engine submission, Cannabis, Marijuana, Pot and tagged , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s